eloralintide tirzepatide A Study of (LY3841136) and Eloralintide With in Participants With Overweight or Obesity Eli Lilly's tirzepatide showed positive

Specifically, the following signals were detected: exenatide (N = 506, ROR = 1.88, 95% CI = 1.722.05, PRR = 1.88, 2 = 205.06, IC = 0.90, IC025 = 0.77), liraglutide (N = 491, ROR = 6.75, 95% CI = 6.177.38, PRR = 6.71, 2 = 2367.04, IC = 2.74, IC025 = 2.59), semaglutide (N = 473, ROR = 5.74, 95% CI = 5.246.28, PRR = 5.71, 2 = 1824.26, IC = 2.50, IC025 = 2.36), dulaglutide (N = 189, ROR = 1.29, 95% CI = 1.121.49, PRR = 1.29, 2 = 12.42, IC = 0.37, IC025 = 0.16), tirzepatide (N = 159, ROR = 1.98, 95% CI = 1.702.32, PRR = 1.98, 2 = 76.95, IC = 0.98, IC025 = 0.75)

The interaction of insulin and pituitary hormone syndromes

MNT had the opportunity to speak with Anton Bilchik, MD, PhD, a surgical oncologist, chief of medicine and director of the Gastrointestinal and Hepatobiliary Program at Providence Saint Johns Cancer Institute in Santa Monica, CA, about this study

Model JFA, Normann RS, Vogt L, et al

Injection technique Subcutaneous injection once weekly